NCT05798923Recruiting
A Phase 2a Study of LAM-001 for the Treatment of PH
A Phase 2a Single-Arm, Open-Label, Exploratory Study to Assess the Effects of LAM-001 (Inhaled Sirolimus) for the Treatment of Pulmonary Hypertension
AI Therapeutics, Inc.Phase 2ClinicalTrials.govdrug
Study focus
- Disease/Condition
- Pulmonary Hypertension
- Drug/Device/Intervention
- LAM-001
- Study type
- Interventional
- Intervention type
- drug
Sponsor & location
- Primary sponsor
- AI Therapeutics, Inc.
- Location
- Boston, United States of America
Timeline & enrollment
- Phase
- Phase 2
- Start date
- Apr 03, 2023
- End date
- Feb 28, 2025
- Enrollment
- 15 participants
Primary outcome
Change from baseline VO2 max
Summary
This is a clinical trial to assess the efficacy and safety of LAM-001 as an add-on therapy
 for the treatment pulmonary hypertension.
ICD-10 classifications
Primary pulmonary hypertensionOther secondary pulmonary hypertensionPulmonary heart disease and diseases of pulmonary circulationPulmonary heart disease, unspecifiedPulmonary valve disorders
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT05798923
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT05798923 through Pure Global AI's free database. This Phase 2 trial is sponsored by AI Therapeutics, Inc. and is currently Recruiting. The study focuses on Pulmonary Hypertension. Target enrollment is 15 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.